2Sardao VA, Oliveira PJ, Holy J, et al. Morphological alterations reduced by doxorubicin on H9c2 myoblasts: nuclear, mitochortdrial, and cytoskeletal targets[J]. Cell Biol Toxicol, 2009, 25(3): 227-43.
3Chung WB, Yi JE, Jin JY, et al. Early cardiac function monitoring for detection of subclinical doxorubicin cardiotoxicity in young adult patients with breast cancer[J] J Breast Cancer, 2013, 16(2): 178-183.
4Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist[J]. Can J Physiol Pharmacol, 2013, 91(8): 601-607.
5Emily H, Angela B, Patrick B, et al. Subclinical and thraccline and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiography study[J]. Heart, 2010, 96(9): 701-707.
6Motoki H, Koyama J, Nakazawa H, et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy[J]. Eur Heart J Cardiovasc Imaging, 2012, 13(1): 95-103.
7Cheung YF, Hong WJ, Chan GC, et al. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy[J]. Heart, 2010, 96(14): 1137-1141.
